Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which Quantum believes could enhance development of MS therapies, including its investigational candidate Lucid-MS.
Quantum submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company holds exclusive rights to Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
The imaging study, conducted in collaboration with Massachusetts General Hospital, aims to validate the [¹⁸F]3F4AP tracer as a tool for directly visualizing demyelination in MS patients. This could provide a more sensitive and specific method for monitoring disease progression and treatment response compared to current imaging techniques. The preliminary data indicating signal in acute MS lesions and gray matter lesions are particularly notable, as gray matter involvement is associated with disability progression in MS.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Beyond Lucid-MS, the company has developed UNBUZZD, a product aimed at reducing alcohol intoxication, and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty payments from sales. However, the current focus remains on the MS imaging study and the potential of Lucid-MS to address unmet needs in MS treatment.
The milestone in patient enrollment brings the study closer to completion, and further data will be critical to confirm the tracer's utility. If successful, this imaging approach could accelerate the development of Lucid-MS and other MS therapies by providing a reliable biomarker for demyelination. For more details, the full press release is available at https://ibn.fm/4IZ0y. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
This development is significant for the MS community and investors, as it represents progress in both diagnostic imaging and therapeutic development. The ability to directly visualize demyelination could transform how MS is monitored and treated, potentially leading to better outcomes for patients.
